PDCD1 and neoplasm: In a 2020 study using a Lewis lung cancer (LLC) mouse model, the combination of Endostar and anti‐PD‐1 therapy not only significantly suppressed tumor growth but also reduced MDSC infiltration within the tumor site [159], indicating the potential of combinations of antiangiogenic agents and ICIs.